BioSpace News Archive

Pharm Country

Biotech Support Group to exhibit at the 67th ASMS Conference on Mass Spectrometry & Allied Topics

Biotech Support Group will exhibit at the annual ASMS Conference, June 2-6, 2019 in Atlanta, GA.

May 6, 2019
·
3 min read
Deals

Invitrocue Releases March 2019 Quarterly And Appoints New Advisor

Invitrocue Limited is pleased to provide its Appendix 4C cash flow statement for the quarter ended March 31, 2019 and to announce the appointment of Dr Sharifuddin Abdul Wahab as Global Insurance Advisor.

May 6, 2019
·
1 min read
Drug Development

With FDA Target Action Date this Month for Zolgensma, AveXis Releases Even More Positive Data

SMA is a severe neuromuscular disease caused by a mutation in the SMN1 gene, which codes for SMN, a protein necessary for motor neuron function.

May 6, 2019
·
3 min read
·
Mark Terry
FDA

Pfizer’s Tafamidis Approved in First for Rare Heart Disease

The approval is a first for the the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). The drug has a list price of $225,000.

May 6, 2019
·
3 min read
·
Alex Keown
Drug Development

6 Companies Report Positive Data in Phase III Clinical Trials

Quite a few companies recently released results from late-stage clinical trials. Here’s a look at some of the top stories, from AveXis, Urovant, Lilly, and more.

May 6, 2019
·
5 min read
·
Mark Terry
Adrenomed AG takes part in three upcoming conferences

Adrenomed AG, the vascular integrity company, announced its participation at three upcoming conferences in Europe and the USA.

May 6, 2019
·
1 min read
Drug Development

GenSight Biologics Announces Presentation of 72-Week Data from the REVERSE Phase III Trial of GS010 at the Annual Meeting of the American Academy of Neurology (AAN)

GenSight Biologics announced that the 72-week results from the REVERSE Phase III clinical trial of GS010 will be presented at the 2019 American Academy of Neurology (AAN) Annual Meeting in Philadelphia, Pennsylvania, United States, May 4-10, 2019.

May 6, 2019
·
5 min read
FDA

Dr. Reddy’s Laboratories Announces the Launch of Testosterone Gel, 1.62% (20.25 mg/1.25 g Pump Actuation) in the U.S. Market

Dr. Reddy’s Laboratories Ltd. announced the launch of Testosterone Gel 1.62%, a therapeutic equivalent generic version of AndroGel® (testosterone gel) 1.62%, approved by the U.S. Food and Drug Administration

May 6, 2019
·
3 min read
Business

Dubai Science Park Signs Partnership Agreement With US Venture Capital Firm 1792 Partners to Attract American Science Companies to Dubai

Agreement Signed During High-level Business Mission to California led by Dubai Investment Development Agency, Dubai Exports

May 6, 2019
·
5 min read
Job Trends

Vizient Announces Product Categories for Quarter 2 National Group Buys Program

Philips Healthcare is the Quarter 2 Featured Supplier

May 6, 2019
·
3 min read